Oncogenic RAS promotes production of reactive oxygen species (ROS), which mediate pro-malignant signaling but can also trigger DNA damage-induced tumor suppression. Thus RAS-driven tumor cells require redox-protective mechanisms to mitigate the damaging aspects of ROS. Here, we show that MutT Homolog 1 (MTH1), the mammalian 8-oxodGTPase that sanitizes oxidative damage in the nucleotide pool, is important for maintaining several KRAS-driven pro-malignant traits in a nonsmall cell lung carcinoma (NSCLC) model. MTH1 suppression in KRAS-mutant NSCLC cells impairs proliferation and xenograft tumor formation. Furthermore, MTH1 levels modulate KRAS-induced transformation of immortalized lung epithelial cells. MTH1 expression is upregulated by oncogenic KRAS and correlates positively with high KRAS levels in NSCLC human tumors. At a molecular level, in p53-competent KRAS-mutant cells, MTH1 loss provokes DNA damage and induction of oncogene-induced senescence. In p53-nonfunctional KRAS-mutant cells, MTH1 suppression does not produce DNA damage but reduces proliferation and leads to an adaptive decrease in KRAS expression levels. Thus, MTH1 not only enables evasion of oxidative DNA damage and its consequences, but can also function as a molecular rheostat for maintaining oncogene expression at optimal levels. Accordingly, our results indicate MTH1 is a novel and critical component of oncogenic KRAS-associated malignancy and its inhibition is likely to yield significant tumor-suppressive outcomes in KRAS-driven tumors.
INTRODUCTION
The RAS oncogene, found in~30% of all cancers, confers multiple malignant traits such as hyperproliferation, enhanced survival signaling, anoikis resistance, increased cell mobility, invasiveness and angiogenesis. 1, 2 Many such malignant traits are mediated by oncogenic reactive oxygen species (ROS) [3] [4] [5] which are elevated by chronic RAS signaling 6 through NADPH oxidase activity and by oncogene-induced mitochondrial dysfunction. 7, 8 Thus, ROS has a dual role in RAS-transformed cells: although their elevation in oncogenic RAS-transformed cells can trigger oxidative DNA damage 7, 9 resulting in cellular senescence [9] [10] [11] or cell death, 12, 13 their presence is also functionally essential to oncogenic RASmediated pro-malignant traits. Hence, RAS-transformed cells must overcome ROS-associated tumor-suppressive effects without eliminating ROS production entirely, an outcome that can be accomplished by increasing levels of non-ROS-scavenging proteins that protect against oxidative damage. In this regard, the major mammalian 8-oxodGTPase, MutT Homolog 1 (MTH1) represents a unique redox-protective mechanism. MTH1 is an 18 kDa Nudix family hydrolase that selectively degrades 8-oxo-dGTP, the most pervasive oxidative DNA base modification, thus preventing its incorporation into genomic DNA during replication or repair. 14 While the long term effects of MTH1 loss are expected to be mutagenic, leading to G to T transversions, our prior work has shown that the acute effects of MTH1 suppression involve genomic strand breaks which trigger premature cell senescence. 15 We have also previously shown that MTH1 overexpression protects normal fibroblasts against HRASV12-induced cellular 8-oxoguanine accumulation, DNA damage and oncogeneinduced senescence (OIS), 9 thus circumventing the first tumor-suppressive step that combats oncogenic RAS-induced transformation. However, the mechanistic involvement of MTH1 in established RAS-driven tumors has not been explored. Given that MTH1 inhibits oncogene-induced DNA damage and OIS but possesses no ROS-detoxifying function, we hypothesized that MTH1 could represent an important adaptive response in activated RAS-harboring tumors due to its ability to minimize the tumor-suppressive effects of oncogenic ROS-induced oxidative DNA damage without actually eliminating ROS.
Elevated levels of MTH1 have been reported in nonsmall cell lung carcinoma (NSCLC), 16 30-50% of which sustain KRAS mutations. However, no functional role has been ascribed to MTH1 in this aggressive tumor type nor are there studies addressing a causal association of MTH1 with KRAS status. In this study, we investigated whether modulation of MTH1 expression via stable retroviral overexpression or lentiviral small-hairpin RNA (shRNA)-mediated suppression regulates proliferation and tumorigenicity of NSCLC cells. In addition, we determined the extent to which these effects are driven by oncogenic KRAS or p53 status, two clinically relevant metrics that determine severity and prognosis of NSCLC. Our results support a critical role for MTH1 in facilitating oncogenic KRASdriven transformation of lung epithelial cells, evading oxidative DNA damage-mediated induction of cellular senescence, and maintaining optimal oncogene levels in KRAS-mutant NSCLC cells that are refractory to senescence induction. Thus, our work describes the first piece of evidence implicating MTH1 as a novel facilitator of KRAS-driven malignancy in NSCLC.
RESULTS

MTH1 suppression impairs in vitro and in vivo proliferation in KRAS-activated NSCLC cells
To determine whether MTH1 loss has functional consequences for the malignancy of KRAS-driven NSCLC cells, we stably knocked down MTH1 expression to 495% using a validated lentiviral MTH1 shRNA construct 9, 15 (Figure 1a ) in the following KRASactivated NSCLC lines: A549 (wildtype (wt) p53, G12S KRAS mutation), H358 (p53 null, G12C KRAS mutation) and H23 (mutant p53, G12C KRAS mutation). MTH1 suppression decreased cell proliferation in all three cell lines, with a complete proliferative arrest observed in A549 small-hairpin MTH1 (shMTH1) cells, consistent with the accompanying elevated senescenceassociated beta-galactosidase (SA-beta-gal) staining (Figures 1b  and c; Supplementary Figure S1A ), increased number of persistent DNA double-strand break gamma-H2AX/53BP1 co-localized foci relative to small-hairpin green fluorescent protein (shGFP) counterpart cells (Supplementary Figure S1B) and a G1/S arrest (Supplementary Figure S1C) . Elevated SA-beta-gal staining and a full proliferative arrest were also observed with two other independent validated Sigma Mission shRNA constructs targeted against MTH1 (Supplementary Figures S1D-G) . We also Figure 1 . MTH1 suppression induces an in vitro and in vivo proliferation defect in KRAS-mutant NSCLC cells. (a) MTH1 suppression via lentiviral shRNA. To confirm MTH1 knockdown, immunoblotting for MTH1 expression was carried out against~25 μg of protein lysates derived from the indicated NSCLC cell lines transduced with either plko.shGFP or plko.shMTH1. GAPDH was used to normalize for protein loading. (b) Proliferation rates in the indicated samples transduced with either shGFP or shMTH1. **P o0.01, *P o0.05. (c) SA-beta-gal activity. As described in the Methods section, SA-beta-gal staining was carried out and quantitated in the indicated samples. (d) MTH1 suppression reduces xenograft tumor formation by KRAS-mutant NSCLC cells. Tumor formation kinetics are shown for the indicated samples. For A549 cells, which were transduced with either the Tet-on shLuc or shMTH1 constructs, doxycycline was administered to the animals at day 14 post injection (indicated by an arrow on the tumor growth curves). (e) Representative images of animals used in the xenograft studies. Animals from each group are shown to the right of the respective tumor curves in d. White arrows indicate sites of subcutaneous tumors. Tumor incidences (tumors formed per sites injected) were as follows: A549 shLuc and shMTH1: 12/12; H358 shGFP: 13/13, H358 shMTH1: 12/13; H23 shGFP: 7/12, H23 shMTH1: 4/12. **P o0.01. (f) In vivo correlation between MTH1 levels and proliferation. Quantification of immunohistochemical staining for Ki67 and MTH1 is shown for the indicated samples as the number of positively stained cells per highpowered field (hpf ) counted. **P o0.01. suppressed MTH1 in H460, another p53-competent KRAS-activated (Q61H mutation) NSCLC cell line, and found that, similar to A549, MTH1 suppression induced a senescent arrest in this cell line as well (Supplementary Figure S2) . However, the rapid proliferation rate of the H460 line selected for cells with incomplete MTH1 knockdown (Supplementary Figure S2A) causing these cells to overtake the bulk population in just over a week ( Supplementary Figures S2B and C) . The inability of this cell line to tolerate MTH1 suppression further underscores a critical role for MTH1 in evading OIS and maintaining a high proliferation rate in KRAS-transformed cells. The p53-nonfunctional H23 or H358 cells did not undergo the proliferative arrest indicative of senescence and accordingly did not exhibit upregulated SA-beta-gal activity upon MTH1 suppression (Figures 1b and c) . Nor did they exhibit a G1/S arrest or increased double-strand break foci formation (data not shown).
Negligible induction of shMTH1-induced cell death was observed in all the above cell lines, as ascertained by flow cytometric analysis of cell death markers, PI/Annexin V, and by cleaved PARP and cleaved caspase-3 protein expression. Minimal differences were observed in these parameters within shGFP-and shMTH1-transduced pairs for each cell line (Supplementary Figures S3A and B) . This lack of cell death upon MTH1 depletion is consistent with findings from another report in which MTH1 was downregulated via miR-145 overexpression. 17 To determine whether MTH1 knockdown also impaired proliferation in an in vivo setting, we monitored subcutaneous xenograft tumor formation in immunocompromised Nu/Nu mice by shMTH1-and control shRNA-transduced counterpart cells. For the A549 cells, which rapidly undergo a senescent arrest ( Figure 1b ) and therefore cannot be injected following constitutive MTH1 knockdown, we utilized a Tet-on inducible plko version 18 expressing the same hairpin sequence as the constitutive shRNA construct. The inducible version provided efficient in vitro and in vivo knockdown upon doxycycline hyclate addition and appeared to be minimally leaky ( Supplementary Figures S4A and  B) . Upon doxycycline hyclate addition, the A549 shMTH1 cells showed significantly reduced tumor formation kinetics relative to their counterpart shLuc cells (Figure 1d) .
However, by using this inducible system, we lost the effect of MTH1 suppression on initial A549 tumor formation because we introduced doxycycline hyclate into the mice only after palpable tumors had formed. To determine whether there was any effect of MTH1 suppression on initial tumor formation efficiency in these cells, we utilized constitutive shMTH1-transduced A549 cells that had adventitiously acquired a somewhat lower (approximately 75-80%) knockdown following shRNA transduction (Supplementary Figure S4C ) and thus retained slower but sustained proliferative ability relative to control cells (Supplementary Figure  S4D) . Monitoring xenograft tumor formation by these cells enabled us to determine that shMTH1 induced an approximately week-long latency in A549 tumor formation at all injection sites relative to the shGFP controls and reduced the incidence as well as size of tumor formation ( Supplementary Figures S4E and F) .
For the H23 and H358 lines, we used the constitutive shMTH1-transduced cells to determine the effects of MTH1 suppression on xenograft tumor formation as these cells did not fully lose proliferative capacity upon MTH1 knockdown (Figure 1b,  Supplementary Figure S1G ). In both cell lines, MTH1 suppression significantly reduced tumor formation relative to counterpart shGFP-transduced cells (Figures 1d and e) . In H23 cells, the least inherently tumorigenic of the three cell lines used (maximal tumor size being~200 mm 3 compared with 500-700 mm 3 for the other two lines, 7/12 tumors formed at shGFP sample injection sites), MTH1 suppression further reduced the size and incidence of tumor formation (4/12 sites) and delayed onset of tumor formation by~2 weeks (Figure 1d ). Consistent with our in vitro data, the shMTH1-induced difference in tumor formation was not due to increased in vivo cell death as there was no perceptible difference in cleaved caspase-3 staining between shGFP and shMTH1 xenograft sections (Supplementary Figure S5) . Immunohistological staining of xenograft tumor sections for the Ki67 panproliferation marker and MTH1 expression confirmed a significant in vivo association between loss of MTH1 expression and reduced proliferation ability (Figure 1f, Supplementary Figure S6 ). For H23, the difference in Ki67 showed a nonsignificant (P = 0.18) trend of decrease between the shGFP and shMTH1 tumors, likely because of the low inherent in vivo proliferation and tumorigenicity of this cell line (Figure 1d ). However, a visual difference in Ki67 staining between shGFP and shMTH1 tumor sections could be readily observed in several of the fields analyzed (Supplementary Figure  S6) , supporting an in vivo shMTH1-induced defect in proliferation leading to reduced tumorigenicity. Collectively these results strongly support a functional role for MTH1 in maintaining the proliferation and tumor formation ability of oncogenic KRASharboring NSCLC cells.
MTH1 suppression induces distinct cell cycle inhibitors depending on p53 status To ascertain the molecular basis of shMTH1-induced proliferative defects observed in the KRAS-mutant NSCLC lines, we determined whether known cell cycle inhibitors of oncogene-driven proliferation were affected. In the p53-competent A549 cells, MTH1 knockdown elevated p53 and p21 cip1/waf1 protein expression ( MTH1 suppression also decreased the expression of phosphoAkt (pAkt), but not phospho-Erk1/2 (pErk1/2), indicating inhibition of PI3K/Akt signaling ( Figure 2b ). Activated Akt inhibition was stronger in the two p53-nonfunctional lines (~50%) when compared with A549 (~28%) at 2 weeks following MTH1 suppression, as determined by densitometry-based comparisons performed on the total Akt-normalized pAkt Western blot signal between shGFP and shMTH1 counterparts. The MTH1 suppression-associated decrease in pAkt and increase in p27 kip1 was also confirmed in vivo in H358 shMTH1 tumor-derived lysates relative to their shGFP tumor counterparts (Figure 2c ).
To determine whether the reduction in pAkt was responsible for the observed increase in p27 kip1 20 and ensuing proliferation defect, we stably expressed a constitutively active form of Akt, Myr-Akt, via a pBABE.neo (pBn) retroviral construct in H358 cells. We also transduced counterpart H358 cells with the empty pBn vector. We subsequently transduced each of these H358 lines with either an shGFP or shMTH1 construct. Comparing these two sets of counterpart lines showed that expression of constitutively activated Akt did not prevent p27 kip1 upregulation ( Figure 2d ) nor did it rescue the shMTH1-associated reduction in proliferation ( Figure 2e ). In fact, relative to the H358 pBn cells, the H358 MyrAkt cells exhibited a greater proliferative defect under MTH1 suppression ( Figure 2e ). We verified that, similar to the H358 control cells, the Myr-Akt H358 cells did not suffer from elevated cell death upon MTH1 suppression (data not shown).
MTH1 maintains oncogenic KRAS-associated malignant traitsMTH1 suppression-induced strand breaks require functional p53 and activated KRAS status DNA damage can trigger tumor suppressor responses, and MTH1 suppression has been reported to induce genomic DNA strand breaks. 15 To determine whether shMTH1 also induced DNA damage in the established KRAS-mutant NSCLC cells, we carried out the single cell gel electrophoresis or 'comet' assay under alkaline conditions on shGFP or shMTH1-transduced A549, H23 and H358 cells. The alkaline assay allows assessment of DNA strand breaks as well as potential strand break-producing oxidative damage, such as persistent abasic sites. The extent of DNA damage in an individual cell is reflected in the amount of unwound DNA migrating from the cell body under electrophoresis, and falls into one of three tail length categories: none, medium or long (Figure 3a) .
In the p53-competent A549 cells, MTH1 suppression increased the extent of alkaline DNA strand breaks, that is, the percentage of total cells with long comet tails ( Figure 3a , Supplementary Figure S7A ). However, in the p53-deficient H23 and H358 cell lines, MTH1 suppression did not increase the extent of DNA strand breakage relative to the control shGFP cells (Figure 3a , Supplementary Figure S7A ).
To determine if this absence of shMTH1-induced DNA damage was due to the lack of functional p53, we transduced a retroviral wt p53 construct (pBLIC.p53) into the p53-null H358 cells ( Figure 3b ) and then suppressed MTH1 in the wt p53-expressing cells (Figure 3c ). Introduction of wt p53 provoked the shMTH1 H358 cells to upregulate p21 cip1/waf1 , enter senescence and develop DNA strand breaks (Figures 3c-e) . Complementarily, suppressing p53 in the A549 cells inhibited shMTH1-induced DNA damage and cellular senescence (Supplementary Figures S7B-F) .
Thus p53 appears to be functionally involved in the generation of shMTH1-induced DNA damage.
Given the increased oxidative stress produced by constitutive KRAS signaling, we wished to determine whether MTH1 suppression-induced DNA strand breaks depend on the presence of activated KRAS. For these experiments, we utilized H1563 NSCLC cells which possess functional p53 and wt KRAS. The H1563 cells possess significantly lower MTH1 baseline levels relative to the p53-competent KRAS-mutant A549 cells (Supplementary Figure S8A) as well as lower total ROS levels (Supplementary Figure S8B) , suggesting a relatively reduced requirement for MTH1 in H1563 cells. We then transduced either a retroviral KRASV12-expressing construct or a control empty vector (pBABE.puro) into H1563 cells and found that in addition to elevating canonical RAS pathway proteins such as pERK and pAkt, KRASV12 also elevated MTH1 expression at both the protein and messenger RNA (mRNA) level (Figure 3f, Supplementary Figure S8C ). As anticipated, introduction of oncogenic KRAS also increased the proliferation rate of H1563 cells (Supplementary Figure S8D) , elevated cellular ROS levels by over twofold (Supplementary Figure S8E) and also upregulated total 8-oxoG levels (Supplementary Figure S8F) .
Unlike their isogenic wt KRAS counterparts, the KRASV12-expressing H1563 cells showed a significant increase in SA-betagal activity (Figure 3g ), p53/p21 cip1/waf1 levels ( Figure 3h ) and DNA strand breaks (Figure 3i ) upon MTH1 suppression. Culturing the H1563 KRASV12 cells at low oxygen (5%) tension, a condition known to reduce endogenous oxidative stress and ameliorate oncogenic RAS-associated antiproliferative effects, 9, 15, 21 prior to MTH1 suppression, inhibited the DNA strand breaks and senescent phenotype observed under ambient oxygen culture (Supplementary Figures S8G and H) . These results collectively affirm that oncogenic KRAS-harboring cells exhibit an enhanced requirement for MTH1 relative to wt KRAS cells, ostensibly to enable evasion of oxidative stress-induced DNA damage and OIS.
MTH1 enhances KRAS-driven oncogenic transformation in p53-abrogated lung epithelial cells Given the relative prevalence of activating KRAS mutations in NSCLC, we wished to determine whether an in vivo correlation exists between MTH1 and KRAS expression levels. To do so, we used quantitative PCR (qPCR) to determine KRAS and MTH1 levels using mRNA derived from a number of NSCLC and matched normal tissue samples from untreated patients. Although the number of samples we utilized was small (n = 7), we nevertheless found that sorting the samples from high-to-low KRAS levels also coordinately segregated the samples according to MTH1 levels ( Figure 4a , the black horizontal line indicating matched normal samples normalized to 1). Linear regression analysis of these data indicated there exists a positive correlation between KRAS and MTH1 levels in these human NSCLC samples (R 2 = 0.65) (Figure 4a ). To determine whether MTH1 levels functionally affect KRAS-mediated oncogenic transformation, we generated stable puromycin-selectable KRASV12-expressing E6/E7 immortalized bronchial epithelial BEAS2B cells and subsequently either overexpressed or suppressed MTH1 using hygromycin-selectable vectors in the KRASV12-transformed BEAS2B cells (Figure 4b ). Empty retroviral vector (pBh) or control lentiviral shRNA (shGFP)-transduced counterpart BEAS2B cells were also established as controls. As observed in the H1563 cells (Figure 3f) , introduction of oncogenic KRAS elevated MTH1 protein levels in the BEAS2B cells (Figure 4b; compare lanes 1 and 2) . More intriguingly, MTH1 suppression led to a decrease in KRAS levels relative to shGFP counterparts (Figure 4b compare lanes 4 vs 5, 4c ). This decrease was associated with reduced pAkt but not pErk1/2 levels, similar to what we observed in Figure 2b (Figure 4b ). We also noticed that MTH1 co-expression elevated KRAS levels relative to the cells expressing KRASV12 alone (Figure 4b, lanes 2 vs 3; Figure 4c , bottom). However, given that co-introduction of the lentiviral shGFP vector also elevated KRAS levels relative to a comparable level (Figure 4b, lanes 3 vs 4; Figure 4c ), we cannot unequivocally attribute this elevation to high MTH1 co-expression. It may be that the lentiviral transduction process selects for high KRASexpressing cells relative to the retroviral transduction process.
Comparison of oncogenic transformation efficiency between the BEAS2B KRASV12/pBh and KRASV12/pBh.MTH1 cells via a 
Chronic MTH1 suppression reduces KRAS expression in vitro and in vivo
The major difference between the p53-competent and the p53-nonfunctional cells vis-à-vis MTH1 suppression appears to be an acute (senescence-associated proliferation arrest) vs chronic (reduced but sustained proliferation) effect. Given the observed shMTH1-dependent reduction in KRAS levels in the BEAS2B cells (Figure 4b ), we speculated that a similar phenomenon may operate in the H23 and H358 cells, particularly as these two cell lines exhibit significantly higher baseline KRAS and concomitant oncogenic ROS levels than A549 cells (Supplementary Figures S9A  and B) . Accordingly we investigated whether proliferation following MTH1 suppression engendered alterations in KRAS expression in the H23 and H358 cells. Both immunoblotting (Figure 5a , Supplementary Figure S9C ) and qPCR (Figure 5b ) indicated that KRAS levels decrease by almost 40% under chronic MTH1 suppression in both H23 and H358 cells, but not in A549 cells which cease to proliferate under MTH1 suppression. This observed decrease does not occur in the H1563 KRASV12-transduced cells (Supplementary Figure S9D) , which also exhibit OIS upon MTH1 suppression (Figures 3g-i) .
The shMTH1-dependent reduction in KRAS expression is also observed in vivo in the H358 and H23 xenograft tumor samples (Figure 5c, Supplementary Figure S9E) . Interestingly, the decrease in KRAS levels does not occur at an early time point (~6 days post transduction) following MTH1 suppression (Supplementary Figure  S9F) but appears to be an adaptive response over time to the loss of MTH1, again underscoring the requirement for MTH1 for maintaining optimal oncogene expression levels in KRAStransformed NSCLC cells. Consistent with the KRAS decrease, pAkt levels in the H358 and H23 xenograft tumor samples continued to decline at 18 days by 61% and 75%, respectively (Figure 5a ) compared with~50% at 14 days post shMTH1 transduction (Figure 2b ). By contrast, the pAkt decline in A549 shMTH1 cells did not go beyond a 30% reduction (compared with 28% at 14 days) (Figure 5a) . Consistent with the data in Figure 2b , pErk1/2 levels did not show a perceptible change between shGFP Figure S9G) . When the H358 shGFP and shMTH1 counterpart cells were cultured for 2 weeks at 5% oxygen, the lower oxygen culture inhibited the shMTH1-induced growth arrest and the decrease in KRAS and pAkt levels observed during ambient oxygen culture (Supplementary Figures S9H and I ). This finding suggested to us that the decline in KRAS levels is perhaps reflective of a cellular response to mitigate oncogene-induced intrinsic oxidative stress.
Consistent with this idea, we found that the gradual decline in KRAS was also reflected in the change in total cellular ROS levels among three KRAS-mutant NSCLC shGFP/shMTH1 pairs. In agreement with our earlier work 9, 15 and with the lack of any direct ROS detoxification functionality for MTH1, we found minimal differences in ROS levels between the shGFP and shMTH1 cells for any of three cell lines within 7 days of shRNA transduction (Figure 5d ). However, when we re-measured ROS levels~2 weeks later, the shMTH1-transduced counterparts from both H23 and H358 cell lines exhibited a pronounced shift towards~35-40% lower ROS levels, whereas the A549 shMTH1 cells exhibited slightly elevated ROS levels relative to the shGFP controls (Figures 5d and e) , consistent with what has been previously reported for senescent cells. 15, 22 It is known that Akt signaling both produces and is stimulated by ROS. 23 Given the observed shMTH1-associated progressive decline in pAkt (Figure 2b MTH1 maintains oncogenic KRAS-associated malignant traits18 days post transduction) in H23 and H358 cells and that Myr-Akt further enhances the shMTH1-induced proliferative defect in H358 cells (Figure 2e ), we measured ROS levels in Myr-Akt H358 cells 2 weeks post transduction with shMTH1. As expected, 23 we found that introduction of Myr-Akt elevated cellular ROS levels in H358 relative to counterparts transduced with the control pBn vector (Supplementary Figure S9J, left) . However, at 18 days after transduction, although the MTH1-suppressed H358 pBn displayed a reduction in cellular ROS levels relative to their shGFP counterparts, the H358 Myr-Akt cells were unable to do so (Supplementary Figure S9J, right) .
Collectively, the above results suggest that p53-nonfunctional cells adapt to MTH1 loss by downregulating ROS-producing mechanisms, including RAS oncogene levels and Akt signaling, and that this adaptation may allow them to continue proliferating, albeit at reduced levels. However, from our present study, we cannot exclude that other redox-regulatory and/or stress-response pathways that mediate proliferation downstream to MTH1 also contribute to this adaptive response.
DISCUSSION
The results presented in this study strongly support the idea that oncogenic KRAS provokes an enhanced requirement for MTH1 function in NSCLC. Oncogenic KRAS elevates MTH1 levels ( Figures  3f and 4b) . In turn, robust MTH1 levels are required in KRASactivated NSCLC cells to maintain proliferation and tumorigenicity through the prevention of tumor-suppressive oxidative DNA damage or preservation of KRAS expression, oncogenic ROS levels and Akt signaling (summarized in Figure 5f ). Accordingly, the overall effect of suppressing MTH1 in KRAS-driven NSCLC cells is either induction of a senescent arrest or selection of slowerproliferating subpopulations with reduced pro-malignant molecular traits.
Our study indicates that two different mechanisms operate to inhibit KRAS-induced malignancy in NSCLC cells when MTH1 expression is suppressed. In a p53-competent context, MTH1 suppression induces an acute effect via OIS-induced cessation of proliferation, resulting from oncogenic KRAS-induced genomic DNA strand breaks (Figures 1b and c; Figure 3 ). Although our study suggests that induction of DNA damage in response to MTH1 suppression depends stringently on functional p53 (Figure 3, Supplementary Figure S7) , the exact molecular mechanism(s) by which MTH1 suppression induces DNA damage is as yet unelucidated. It is known that NSCLC cells sustain lost or impaired 8-oxoguanine glycosylase (hOGG1) activity, 24, 25 and it has further been suggested that this deficiency leaves MTH1 as the predominant inhibitor of genomic 8-oxoG accumulation in NSCLC cells. 26 Thus we speculate that reduced MTH1 expression and function in the context of impaired hOGG1 activity and RAS oncogene-induced genotoxic stress is likely to disrupt base excision repair coordination and efficient ligation at multiple genomic 8-oxoG sites, 27 leading to unrepaired DNA damage. An analogous mechanism has been recently identified involving uracil-N-glycosylase activity-induced DNA damage in tumor cells in the presence of elevated genomic dUTP incorporation. 28 The second tumor suppressor mechanism invoked by MTH1 suppression occurs in a p53-nonfunctional context and provides insights into the chronic effects of MTH1 loss, whereby the MTH1-suppressed cells do not entirely lose proliferative ability. As p53 is lost or mutated in 50% of tumors, this effect of MTH1 suppression is likely to be translationally important. MTH1 inhibition in p53-nonfunctional H23 and H358 cell lines does not produce DNA damage relative to control cells (Figure 3a) , which is consistent with the ability of these cells to survive and proliferate despite MTH1 suppression. It is likely that the p53-deficient status of H358 and H23 cells has caused them to acquire compensatory mechanisms that enable proliferation despite pervasive genomic instability. The inability of MTH1 suppression to elevate DNA strand breakage in these cells likely reflects the consequences of such compensation. In addition, p53 can modulate cellular ROS levels through a number of pro-oxidant mechanisms 29 and control base excision repair mechanisms that remove genomic 8-oxoG, 30 both factors which could contribute to p53-nonfunctional cells not incurring shMTH1-induced DNA damage. Thus, while a definitive molecular delineation of p53's role in this phenomenon is likely to be complicated and beyond the scope of this study, our findings are consistent with the idea that nonfunctional p53 confers resistance to DNA damaging agents. 31, 32 Nevertheless, we find that MTH1 suppression in the p53-nonfunctional H358 and H23 cells reduced in vitro and in vivo proliferation and elevated p27 kip1 expression, both positive prognostic factors for KRAS-driven NSCLC. 33 More significantly, MTH1 suppression in the p53-nonfunctional cells reduced KRAS expression in vitro and in vivo ( Figure 5 ). Several studies have shown that reducing levels of oncogenic KRAS impairs proliferative and tumorigenic capacity in NSCLC and other RAS-driven tumor cells. [34] [35] [36] [37] Thus, MTH1 inhibition ostensibly suppresses the propagation of high KRAS-expressing cells, which possess concomitantly greater capacity for malignant growth and signaling. Furthermore, the shMTH1-associated reduction in pAkt levels ( Figures 2b and c and 5a ) is very similar to what was observed in KRAS-suppressed H23 and H358 cells lines in another study. 35 Previous studies have established a critical role for ROS in promoting hyperactivated Akt signaling and RAS-driven tumorigenesis. 38, 39 Thus the observed reduction in ROS levels in shMTH1 H23 and H358 cells (Figures 5d and e) likely also impacts the observed decrease in activated Akt (Figures 2b and c,  Figure 5a ). Furthermore, inhibition of Akt signaling is associated with resistance to RAS-induced oxidative stress and antiproliferative effects. 23 This is consistent with our findings regarding the shMTH1-induced reduction in Akt signaling in proliferating H23 and H358 cells (Figures 2b and 5a ) and with the enhancement of shMTH1-induced proliferation defect in H358 Myr-Akt cells (Figure 2e) , that do not reduce cellular ROS levels upon MTH1 suppression (Supplementary Figure S9J) .
Further studies will be required to understand the mechanisms by which MTH1 can act as a molecular rheostat for KRAS levels and accordingly its downstream pro-malignant effects. The KRAS promoter consists of G-rich tracts, 40 which constitute hotspots for 8-oxoG accumulation and concomitant DNA breaks 41 either via direct oxidation or incorporation of 8-oxo-dGTP. Thus continued proliferation and DNA replication under MTH1 suppression could either lead to KRAS promoter mutation through elevated 8-oxoG 41 or 8-oxoG-associated structural alterations in promoter Gquadruplexes. 40, 42, 43 Such a possibility would also explain the gradual rather than acute nature of KRAS decrease as it would take several replication cycles to produce steady-state oxidative damage in the KRAS promoter region.
It has proven difficult to directly target oncogenic RAS in tumors. 44 The ability of MTH1 suppression to provoke DNA damage-induced OIS or downregulate oncogene levels and concurrent downstream traits, such as transformation and proliferation, suggests that targeting MTH1 in lieu of KRAS is likely to produce similar tumor-inhibitory effects. Two recent articles 45, 46 published while our manuscript was in revision characterize synthetic MTH1 inhibitors and support our conclusion that pharmacologic inhibition of MTH1 in human tumors possesses significant therapeutic promise. Thus we believe the findings presented herein provide valuable context for targeting MTH1 in KRAS-driven NSCLC and potentially other KRAS-driven tumors. Cell lines and culture BEAS2B, A549, H460, H23, H358 and H1563 cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). All cells were grown at 37°C in 21% or 5% oxygen where indicated and 5% CO 2 . BEAS2B cells were maintained in Dulbecco's modified Eagle's medium (DMEM): F12 complete base media supplemented with 10% fetal bovine serum and 100 units per ml of penicillin-streptomycin. A549, H23, H358 and H1563 cells were maintained in RPMI-1640 complete base media supplemented with 10% fetal bovine serum and 100 units per ml of penicillinstreptomycin (Life Technologies, Grand Island, NY, USA).
MATERIALS AND METHODS
Soft agar colony formation assay
Noble agar (BD Biosciences, Franklin Lakes, NJ, USA) at a 2.4% stock concentration was added to a solution containing Dulbecco's modified Eagle's medium, 20% fetal bovine serum and 200 units of streptomycin: penicillin/fungizone to yield a 0.6% bottom agar solution. A 0.3% top agar solution containing suspended target cells was layered over pre-solidified bottom agar in 6-cm-dishes. The assay was set up in triplicate per sample, with 10 4 cells seeded per dish. Once a week, the top agar was refreshed with 100-200 μl of fresh complete media. Three weeks post seeding, the dishes were imaged and the colonies were scored using the Quantity One software on a Chemidoc (BioRad, Hercules, CA, USA) machine.
DNA constructs and viral transduction
The pBABE.MTH1 overexpression and pBLIC.p53 retroviral constructs were cloned in our laboratory. 9, 47 The retroviral pBABE.puro.KRASV12 construct (plasmid 9052), the pBABE.neo.Myr-AKT1 construct (15266) and the inducible lentiviral plko-TET-on backbone 18 construct were obtained from Addgene (Cambridge, MA, USA). Viral supernatant production in HEK 293T cells and infection of target cells were performed as described previously. 48 Transduced cells were selected in 2.5 μg/ml puromycincontaining, 100 μg/ml hygromycin-containing, 10 μg/ml blastocidincontaining or 500 μg/ml G418-containing media for a minimum period of 5-7 days (corresponding to the time taken for untransduced cells to die completely in selection media).
The plko.shMTH1 and plko.shGFP constructs have been previously described. 9, 15 The plko-Tet-on.shMTH1 target sequence is the same as the constitutive shMTH1 target. The plko-Tet-on.shLuc target sequence is: 5′-CTTCGAAATGTCCGTTCGGTT-3′. Two additional Sigma Mission shMTH1 constructs used in the Supplementary Data section were targeted to the following sequences:
shMTH1-2 (TRCN0000288947): 5′-CCTGAGCTCATGGACGTGCAT-3′ shMTH1-3 (TRCN0000050132): 5′-CGAGTTCTCCTGGGCATGAAA-3′
Cell proliferation measurements
To determine cell proliferation rates, 5 × 10 4 cells were seeded in 10-cm dishes and cell counts were carried out in triplicate every 24 h over a 4-day period, via a hemocytometer (VWR International LLC, Radnor, PA, USA). Fresh media was added every 2-3 days to dishes not being counted. A minimum of two independent cell proliferation curves were established per sample pair being assayed.
Western blotting
Western blotting was carried out as previously described. 47 Blots were probed with antibodies against the following proteins: MTH1 (NB100-109, Novus Biologicals, Littleton, CO, USA), p53 (sc-126, Santa Cruz Biotech, Santa Cruz, CA, USA), p21 cip1/waf1 (sc-817, Santa Cruz Biotech), pAkt (4060, Cell Signaling, Danvers, MA, USA) total Akt (9272, Cell Signaling), cleaved PARP (9541, Cell Signaling), pErk1/2 (9101, Cell Signaling), total Erk (9102, Cell Signaling), p27 kip1 (sc-528, Santa Cruz Biotech), KRAS (sc-30, Santa Cruz Biotech), tubulin (sc-8035, Santa Cruz Biotech), actin (ab82266, Abcam, Cambridge, MA, USA) and GAPDH (ab9485, Abcam). Western blotting images represent data consistent with a minimum of two independently established sets of samples. Densitometry of images was carried out via the ImageJ (NIH software, downloaded from http://imagej.nih.gov/ij) Analyze Gels module.
qPCR analysis
The mRNA preparation from the tumor samples was accomplished as described previously 49 using the Trizol method and the RNeasy kit (Qiagen, Valencia, CA, USA). Using 1.0 μg of RNA, complementary DNA was synthesized with the High Capacity cDNA Reverse Transcription kit (cat# 4368814; Life Technologies). The qPCR reaction was set up with 1.0 μl of complemetary DNA and 20X TaqMan probes and TaqMan Universal PCR Master Mix (cat# 4324018; Life Technologies) in a 15 μl total volume. Samples were run in triplicate on an Applied Biosystem (Life Technologies) Real-Time machine using a StepOne program at 95°C for 10 min and 40 cycles of the following: 95°C for 15 s and 60°C for 1 min. Gene expression levels were calculated using the 2 − ΔΔCT method. 50 The following genespecific TaqMan primer/probe sets were used: MTH1 (Hs00159343_m1), KRAS (Hs00364282_m1), actinB (internal normalization control; Hs99999903_m1)
ROS measurements
The assay was carried out as described previously 15, 51 via staining with 10 μM 5-(and-6)-chloromethyl-2′,7′-dichlorofluorescein diacetate (C6827; Life Technologies) for 25 min at 37°C. Flow cytometric analysis was conducted on an Accuri C6 cytometer (BD Biosciences).
Comet assay
The comet assay was carried out according to the comet assay kit (Trevigen, Gaithersburg, MD, USA) instructions for alkaline unwinding and electrophoresis conditions. Gel electrophoresis was carried out at 21V for 30 min at 4°C. Positive and negative control cells provided by Trevigen were run along with each sample to ensure that lack of 'tails' in a sample or long 'tails' were not due to technical issues. A minimum of 100 individual cells per sample were scored in duplicate from two independent experiments, with the DNA tail lengths being visually categorized as either long, medium or none in double-blind scoring.
SA beta-gal assay SA-beta-gal staining was carried out as described elsewhere. 51, 52 To quantify positive staining, 4100 cells were counted for each sample over multiple fields of view, excluding fields at the very edge. Results represent data from a minimum of two independent experiments.
Xenograft tumor experiments
All animal protocols were approved by the University of Miami Institutional Animal Care and Use Committee. Approximately 10 6 cells were resuspended in 100 μl of Matrigel (BD Biosciences), diluted at a ratio of 1:2 in RPMI-1640 media and injected subcutaneously using a 25-gauge needle into the flanks of 6-week-old immunocompromised mice (Nu/Nu; Harlan Laboratories, Inc, Frederick, MD, USA). A minimum of 12 sites was injected per sample. Tumor length, width and height were measured biweekly using electronic precision calipers (VWR). Tumor volumes were calculated according to the following formula: 4/3 × 3.14 × (height/2 × width/ 2 × length/2) or 0.52 × (height × width × length). Tumor-bearing animals were euthanized before tumors could exceed a volume of 1 cm 3 . For the animals injected with plko-Tet-on inducible shRNA constructs, once palpable tumors were observed (around 14 days post injection), both the shLuc and shMTH1 groups were continuously dosed via oral ingestion with 2 mg/ml doxycycline hyclate (Sigma, St Louis, MO, USA) in a 5% sucrose solution.
Immunohistological and double immunofluorescent staining
For immunostaining, tissues were fixed overnight in formalin and stained for human MTH1 (1/150 dilution; Novus Biologicals, Littleton, CO, USA) and pan-proliferation marker Ki67 (1/500 dilution; NCL-Ki67p, Leica Microsystems, Buffalo Grove, IL, USA) as described previously. 53 Images were photographed using a Nikon Microphot-FXA microscope and a Nikon Coolpix 4300 digital camera (Nikon Instruments, Inc., Melville, NY, USA). For quantification, three random high-powered (200X) fields from each section MTH1 maintains oncogenic KRAS-associated malignant traits
